Skip to main content
OpenTrials
Completed

NCT Number: NCT01816503

Fentanyl Matrix Application for Cancer Pain: Multicenter, Prospective, Observational Study

The purpose of this study is to show the clinical usefulness of fentanyl matrix by measuring satisfaction with pain treatment after administering fentanyl matrix in patients whose pain was not controlled sufficiently with the previous analgesic use in real practice at the investigator's discretion.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pain Cancer Pain Neurologic Manifestations Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

20 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

This is a multi-center, open-label (all people know the identity of the intervention), prospective (the patients are identified and then followed forward in time for the outcome of the study) observational study. The study population comprises patients who are admitted to a study center during the study period and are receiving a strong oral long-acting opioid analgesic but deemed to control pain insufficiently. Since this study is an observational study conducted in real practice, a dose of fentanyl matrix should be adjusted depending on an individual patient's response at the investigator's discretion. However, for the patients whose pain is not sufficiently controlled despite administration of strong long-acting opioid analgesics, the minimum initial dose will be fentanyl matrix 75 micrograms/h and the investigator can adjust dosage according to the degree of the patients' pain control during the 9 days of the study period.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients complaining of cancer pain which requires administration of long-acting opioid analgesics
  • Patients whose pain is not sufficiently controlled despite administration of strong long-acting opioid analgesics
  • Patients who are deemed to need an initial minimum dose of fentanyl matrix 75 micrograms/h
  • Patients who signed the informed consent form

Exclusion criteria

  • Patients with a history of or current drug or alcohol abuse
  • Childbearing women who are pregnant or likely to be pregnant during the study period and men who are neither infertile nor willing to refrain from sexual relations but whose partner does not conduct an effective contraception
  • Patients who are unable to use a transdermal system due to skin disease
  • Patients with history of hypersensitivity to opioid analgesics
  • Patients who are not eligible for the study participation based on warnings, precautions and contraindications in the package insert of the study drug at the investigator's discretion

Treatment and study plan

No intervention

Drug

This is an observational study. The minimum initial dose will be fentanyl matrix 75 micrograms/h and the investigator can adjust the dosage according to the degree of the patients' pain control during the 9 days of the study period. Fentanyl matrix is a transdermal patch that is applied on the patient's skin.

Primary outcomes

  1. The percentage of patients who are very satisfied or satisfied with the pain treatment after the study drug administration

    Time frame: Day 10

    The overall satisfaction is measured by a 5-point scale. Patients' answers are rated as: "very satisfied", "satisfied", "fair", "dissatisfied", or "very dissatisfied".

Secondary outcomes

  1. The change from baseline in pain intensity

    Time frame: Baseline, up to Day 10

    The mean pain intensity the patient experienced over the last 24 hours will be measured through Numeric Rating Scale (NRS); 0 = no pain, 10 = worst pain imaginable.

  2. The change from baseline in Karnofsky Performance Status Scale

    Time frame: Baseline, Day 10

    Karnofsky Performance Status Rating Scale is a tool to assess cancer patients' physical functioning. Scores range from 0 per cent (dead) to 100 per cent (normal, no complaints, no evidence of disease) in a unit of 10 per cent to indicate a level of overall daily activity performance status.

  3. Sleep disturbance caused by the number of awakening caused by pain the patient experienced over the last night

    Time frame: 10 days

    Patients indicate in a Numeric Rating Scale (NRS) the number of awakening from sleep due to pain in the previous night: not awakened, once, twice, more than 3 times, or could not sleep.

  4. Sleep disturbance caused by pain the patient experienced over the last 24 hours

    Time frame: 10 days

    Patients indicate in a Numeric Rating Scale (NRS) the sleep disturbance caused by pain experienced over the last 24 hours, where 0= not disturbing at all, and 10= very disturbing.

  5. The change from baseline in Clinical Global Impression - Improvement (CGI-I)

    Time frame: Baseline, Day 10

    CGI-I measures the overall improvement of the patient's condition compared to baseline, as follows; 1 = Improved very much, 2 = Improved a lot, 3 = Improved a little, 4 = No change, 5 = Aggravated a little, 6= Aggravated a lot, 7= Aggravated very much.

  6. Patient's Global Assessment

    Time frame: Day 10

    This tool assesses how effective the study drug has been in pain treatment during the study period. The patient will assess the effectiveness from his/her viewpoint at visit 10 on a 5-point rating scale; 1 = not effective, 2 = fair, 3 = effective, 4 = very effective, 5 = very much effective.

  7. Investigator's Global Assessment

    Time frame: Day 10

    This tool assesses how effective the study drug has been during the study period. The investigator will assess the effectiveness from his/her viewpoint at Visit 10 on a 5-point rating scale; 1 = not effective, 2 = fair, 3 = effective, 4 = very effective, 5 = very much effective.

  8. Dose of fentanyl matrix

    Time frame: 9 days

    The dose of fentanyl matrix used throughout the study.

Sponsors and collaborators

Lead sponsor

Janssen Korea, Ltd., Korea

Industry

Registry information

Official study title

High-dose Fentanyl Matrix Application for Cancer Pain: Multicenter, Prospective, Observational Study

Important dates

Study start
2008
Primary completion
2009
Study completion
2009
First posted
Mar 22, 2013
Registry last updated
Mar 22, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.